Clinical Trial Update: VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo [Phase 3]

View source ↗

Summary

This is a completed Phase 3 rollover trial (VX-950-TiDP24-C219) for Hepatitis C in which patients in the control group of the C216 study received Telaprevir; re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Telaprevir (telaprevir)

Snippet

Sponsor: Janssen Infectious Diseases BVBA | Conditions: Hepatitis C, Chronic | Phase 3 | Status: COMPLETED | Results posted: 2013-04-19